A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Two-Staged, Fixed Design Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Overweight/Obese Patients of Type 2 Diabetes Mellitus Inadequately Controlled on Metformin, Sulphonylurea, or Both.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs P 2202 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 03 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 Aug 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01674348)